TABLE 1.
Baseline characteristics of study participants1
| All (n = 15) | CKD (n = 11) | Controls (n = 4) | 2 | |
| Age (y) | 64 ± 143 | 67 ± 14 | 56 ± 12 | 0.18 |
| M [n (%)] | 6 (40) | 4 (36) | 2 (50) | 0.63 |
| White [n (%)] | 14 (93) | 10 (91) | 4 (100) | 0.53 |
| Weight (lb) | 175 ± 40 | 179 ± 43 | 164 ± 27 | 0.52 |
| Height (in) | 66.4 ± 3.3 | 65.9 ± 3.0 | 67.8 ± 4.1 | 0.37 |
| eGFR (mL · min−1 · 1.73 m−2) | 46 ± 20 | 36 ± 7 | 75 ± 14 | <0.001 |
| Phosphate (mg/dL) | 3.59 ± 0.55 | 3.56 ± 0.60 | 3.65 ± 0.40 | 0.80 |
| Calcium (mg/dL) | 9.32 ± 0.40 | 9.20 ± 0.37 | 9.68 ± 0.22 | 0.34 |
| FGF23 (RU/mL) | 218 ± 120 | 271 ± 102 | 88 ± 17 | <0.01 |
| Intact PTH (pg/mL) | 62 ± 44 | 76 ± 44 | 27 ± 18 | 0.02 |
| 1,25(OH)2 (pg/mL) | 38.3 ± 12.1 | 36.5 ± 13.3 | 43.3 ± 6.8 | 0.36 |
1
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor-23; PTH, parathyroid hormone; RU, relative units; 1,25(OH)2, 1,25-dihydroxyvitamin D.
2
For CKD patients compared with controls.
3
Mean ± SD (all such values).